Buscar
Mostrando ítems 1-10 de 72
Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: Interaction with nitric oxide
(Elsevier Science BvAmsterdamHolanda, 2006)
Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs
(Blackwell PublishingOxfordInglaterra, 2007)
Inhibitory effects on human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase
(Pergamon-elsevier Science LtdOxfordInglaterra, 2005)
Long-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model
(Wiley-blackwellMaldenEUA, 2011)
Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism
(ELSEVIER SCIENCE BV, 2008)
The current therapy of acute pulmonary embolism is focused on removing the mechanical obstruction of the pulmonary vessels. However, accumulating evidence suggests that pulmonary vasoconstriction drives many of the hemodynamic ...
Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle
(Elsevier Science BvAmsterdamHolanda, 2010)
Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator
(Blackwell PublishingOxfordInglaterra, 2005)
Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum
(Elsevier Science BvAmsterdamHolanda, 2003)
Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats
(Lippincott Williams & WilkinsPhiladelphiaEUA, 2006)
Long-Term Administration of BAY 41-2272 Prevents Bladder Dysfunction in Nitric Oxide-Deficient Rats
(Wiley-blackwellMaldenEUA, 2011)